ESH CML Highlights: Michele Baccarani Symposium - understanding the significance of mutations in CML
Managing cardiovascular risks associated with lifelong TKI therapy in CML
TKI-related toxicities in CML & the importance of long-term monitoring
Exciting advances in DLBCL: molecular characterization of subtypes & novel immunotherapeutic agents
Unmet clinical needs in BPDCN: improving diagnosis and treatment approaches
Smart Wearables & Heartbeats Part 2: Athletes
EHA 2023 CLL highlights
How COVID-19 has impacted patients with hematological malignancies
BTK inhibitors for CLL at EHA 2021
MRD-driven addition of ibrutinib to venetoclax for CLL
Круглий стіл з обговоренням в секції Аритмологія - XXIII НАЦІОНАЛЬНИЙ КОНГРЕС КАРДІОЛОГІВ УКРАЇНИ
Rhythmologie Update 2021 / Tachykardiomyopathie (#SyGAAD_Webinars 2021) (3)
Leucemie, come gestire le complicanze infettive delle terapie target?
Qui appareiller par un pacemaker ?. MAC- N.LELLOUCHE
03-«Неудобные вопросы в интервенционном лечении ХСН»
La nuova normativa europea che regola gli studi clinici in Europa accelererà lo sviluppo di farmaci
Tầm soát rung nhĩ và xử trí rung nhĩ dưới lâm sàng
